Application of DMXAA in preparation of hypoglycemic drugs

A technology for lowering blood sugar and drugs, which is applied in the application field of DMXAA in the preparation of hypoglycemic drugs, can solve the problems of no DMXAA, etc., achieve the effect of lowering blood sugar levels and good development and application prospects

Active Publication Date: 2019-01-18
SHANGHAI FIRST PEOPLES HOSPITAL
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no report on the role of DMXAA in lowering blood sugar

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of DMXAA in preparation of hypoglycemic drugs
  • Application of DMXAA in preparation of hypoglycemic drugs
  • Application of DMXAA in preparation of hypoglycemic drugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] Example 1: Effect of DMXAA Single Administration on Glucose Tolerance in Mice

[0027] Glucose-loaded mice were used to study the hypoglycemic effect of a single administration of DMXAA on mice.

[0028] 1. Animals

[0029] Healthy C57 mice, female, weighing 18-20 g, were divided into 2 groups with 10 mice in each group. C57 mice were purchased from Shanghai Slack Experimental Animal Co., Ltd., with a quality certificate number (animal certificate number: SCXK (Shanghai) 2007-0005). C57 mice were kept in a clean animal room.

[0030] 2. Administration and grouping

[0031] DMXAA was prepared with 0.9% saline.

[0032] Group the experimental rats into groups:

[0033] Control group: given the same amount of normal saline as the drug experiment group, intraperitoneal injection.

[0034] Drug group: DMXAA of 25 mg / kg was given by intraperitoneal injection.

[0035] 3. Experimental method

[0036] Adult male C57 mice (8 weeks old) were divided into two groups: the c...

Embodiment 2

[0039] Embodiment 2: The impact of DMXAA multiple administration on mouse glucose tolerance

[0040] Glucose-loaded mice were used to study the hypoglycemic effect of multiple administrations of DMXAA on mice.

[0041] 1. Animals

[0042] Healthy C57 mice, female, weighing 18-20 g, were divided into 2 groups with 10 mice in each group. C57 mice were purchased from Shanghai Slack Experimental Animal Co., Ltd., with a quality certificate number (animal certificate number: SCXK (Shanghai) 2007-0005). C57 mice were kept in a clean animal room.

[0043] 2. Administration and grouping

[0044] DMXAA was prepared with 0.9% saline.

[0045] Group the experimental rats into groups:

[0046] Control group: given the same amount of normal saline as the drug experiment group, intraperitoneal injection.

[0047] Drug group: DMXAA of 25 mg / kg was given by intraperitoneal injection.

[0048] 3. Experimental method

[0049] Adult male C57 mice (8 weeks old) were randomly divided into ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the technical field of medicine, and specifically discloses application of DMXAA in preparation of hypoglycemic drugs. The application of DMXAA in preparation of hypoglycemicdrugs is disclosed for the first time. The results showed that DMXAA could reduce the blood glucose level of mice, and had no effect on the body weight of mice. Therefore, DMXAA could be used as a hypoglycemic drug and had a good market prospect.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to the application of DMXAA in the preparation of hypoglycemic drugs. Background technique [0002] my country is a big country with diabetes, the prevalence of diabetes has risen to 9.7%, and the number of patients is as high as 92.4 million. Diabetes is a group of metabolic diseases characterized by hyperglycemia. Hyperglycemia is caused by defective insulin secretion or impaired biological action, or both. The long-term high blood sugar in diabetes leads to chronic damage and dysfunction of various tissues, especially the eyes, kidneys, heart, blood vessels, and nerves. [0003] There is currently no cure for diabetes, but it can be controlled with medication. Hypoglycemic drugs mainly include insulin and its analogs, sulfonylureas, metformin, α-glucosidase inhibitors, thiazolidinedione derivatives, GLP-1 receptor agonists, DPP-4 enzyme inhibitors, etc. . [0004] DMXAA (5,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/352A61P3/10A23L33/00
CPCA23V2002/00A61K31/352A23L33/00A61P3/10A23V2200/328
Inventor 章越凡范国荣张磊于永生唐原君汪硕闻
Owner SHANGHAI FIRST PEOPLES HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap